Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 1;85(9):799-805.
doi: 10.1212/WNL.0000000000001896. Epub 2015 Aug 5.

Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension

Collaborators, Affiliations

Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension

Michael Wall et al. Neurology. .

Abstract

Objectives: Determine potential risk factors for progressive visual field loss in the Idiopathic Intracranial Hypertension Treatment Trial, a randomized placebo-controlled trial of acetazolamide in patients with idiopathic intracranial hypertension and mild visual loss concurrently receiving a low sodium, weight reduction diet.

Methods: Logistic regression and classification tree analyses were used to evaluate potential risk factors for protocol-defined treatment failure (>2 dB perimetric mean deviation [PMD] change in patients with baseline PMD -2 to -3.5 dB or >3 dB PMD change with baseline PMD -3.5 to -7 dB).

Results: Seven participants (6 on diet plus placebo) met criteria for treatment failure. The odds ratio for patients with grades III to V papilledema vs those with grades I and II was 8.66 (95% confidence interval [CI] 1.65-∞, p = 0.025). A 1-unit decrease in the number of letters correct on the ETDRS (Early Treatment Diabetic Retinopathy Study) chart at baseline was associated with an increase in the odds of treatment failure by a factor of 1.16 (95% CI 1.04-1.30, p = 0.005). Compared with female participants, the odds ratio for male participants was 26.21 (95% CI 1.61-433.00, p = 0.02). The odds of treatment failure were 10.59 times higher (95% CI 1.63-116.83, p = 0.010) for patients with >30 transient visual obscurations per month vs those with ≤30 per month.

Conclusions: Male patients, those with high-grade papilledema, and those with decreased visual acuity at baseline were more likely to experience treatment failure. All but one of these patients were treated with diet alone. These patients should be monitored closely and be considered for aggressive treatment of their idiopathic intracranial hypertension.

PubMed Disclaimer

Figures

Figure
Figure. Classification tree analysis
(A) Classification tree analysis with 0.05 significance level for splitting shows high-Frisén-grade papilledema and daily transient visual obscurations as risk factors for poor outcome. (B) Classification tree analysis with 0.1 significance level for splitting shows high-grade papilledema, frequent transient visual obscurations, and reduced visual acuity as risk factors for poor visual outcome.

References

    1. Smith JL. Whence pseudotumor cerebri? J Clin Neuroophthalmol 1985;5:55–56. - PubMed
    1. Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014;311:1641–1651. - PMC - PubMed
    1. Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri: follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982;39:461–474. - PubMed
    1. Wall M, George D. Idiopathic intracranial hypertension: a prospective study of 50 patients. Brain 1991;114:155–180. - PubMed
    1. Friedman DI, McDermott MP, Kieburtz K, et al. The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol 2014;34:107–117. - PubMed

Publication types

MeSH terms